Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine

Publication Date:
2018-03-12
Publisher:
Wiley-Blackwell
Print ISSN:
0007-0963
Electronic ISSN:
1365-2133
Topics:
Medicine
Published by:
http://www.wiley.com/wiley-blackwell
_version_ 1836398839091691522
autor B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
beschreibung patients with moderate to severe psoriasis are difficult to treat with topical therapy only and they usually require additional systemic therapy. Despite this, a significant percentage of patients on these therapies shows an inadequate response to these drugs. Treatment decisions are often difficult as they usually rely on subjective terms. Therefore, finding indicators that predict efectiveness or failure to classical systemic therapy is an urgent need. The objective of this study was to analyse whether the phenotype of peripheral blood mononuclear cells (PBMC) would be different in responder or non-responder patients to classical systemic therapy, and thus could be used as a efectiveness predictor of this therapy effectiveness. These predictor markers could help physicians to choose the best individualised treatment for psoriasis patients. This article is protected by copyright. All rights reserved.
citation_standardnr 6201722
datenlieferant ipn_articles
feed_id 5432
feed_publisher Wiley-Blackwell
feed_publisher_url http://www.wiley.com/wiley-blackwell
insertion_date 2018-03-12
journaleissn 1365-2133
journalissn 0007-0963
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher Wiley-Blackwell
quelle British Journal of Dermatology
relation http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fbjd.16537
search_space articles
shingle_author_1 B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
shingle_author_2 B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
shingle_author_3 B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
shingle_author_4 B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
shingle_catch_all_1 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
patients with moderate to severe psoriasis are difficult to treat with topical therapy only and they usually require additional systemic therapy. Despite this, a significant percentage of patients on these therapies shows an inadequate response to these drugs. Treatment decisions are often difficult as they usually rely on subjective terms. Therefore, finding indicators that predict efectiveness or failure to classical systemic therapy is an urgent need. The objective of this study was to analyse whether the phenotype of peripheral blood mononuclear cells (PBMC) would be different in responder or non-responder patients to classical systemic therapy, and thus could be used as a efectiveness predictor of this therapy effectiveness. These predictor markers could help physicians to choose the best individualised treatment for psoriasis patients. This article is protected by copyright. All rights reserved.
B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
Wiley-Blackwell
0007-0963
00070963
1365-2133
13652133
shingle_catch_all_2 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
patients with moderate to severe psoriasis are difficult to treat with topical therapy only and they usually require additional systemic therapy. Despite this, a significant percentage of patients on these therapies shows an inadequate response to these drugs. Treatment decisions are often difficult as they usually rely on subjective terms. Therefore, finding indicators that predict efectiveness or failure to classical systemic therapy is an urgent need. The objective of this study was to analyse whether the phenotype of peripheral blood mononuclear cells (PBMC) would be different in responder or non-responder patients to classical systemic therapy, and thus could be used as a efectiveness predictor of this therapy effectiveness. These predictor markers could help physicians to choose the best individualised treatment for psoriasis patients. This article is protected by copyright. All rights reserved.
B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
Wiley-Blackwell
0007-0963
00070963
1365-2133
13652133
shingle_catch_all_3 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
patients with moderate to severe psoriasis are difficult to treat with topical therapy only and they usually require additional systemic therapy. Despite this, a significant percentage of patients on these therapies shows an inadequate response to these drugs. Treatment decisions are often difficult as they usually rely on subjective terms. Therefore, finding indicators that predict efectiveness or failure to classical systemic therapy is an urgent need. The objective of this study was to analyse whether the phenotype of peripheral blood mononuclear cells (PBMC) would be different in responder or non-responder patients to classical systemic therapy, and thus could be used as a efectiveness predictor of this therapy effectiveness. These predictor markers could help physicians to choose the best individualised treatment for psoriasis patients. This article is protected by copyright. All rights reserved.
B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
Wiley-Blackwell
0007-0963
00070963
1365-2133
13652133
shingle_catch_all_4 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
patients with moderate to severe psoriasis are difficult to treat with topical therapy only and they usually require additional systemic therapy. Despite this, a significant percentage of patients on these therapies shows an inadequate response to these drugs. Treatment decisions are often difficult as they usually rely on subjective terms. Therefore, finding indicators that predict efectiveness or failure to classical systemic therapy is an urgent need. The objective of this study was to analyse whether the phenotype of peripheral blood mononuclear cells (PBMC) would be different in responder or non-responder patients to classical systemic therapy, and thus could be used as a efectiveness predictor of this therapy effectiveness. These predictor markers could help physicians to choose the best individualised treatment for psoriasis patients. This article is protected by copyright. All rights reserved.
B. Hernández-Breijo, T. Jurado, E. Rodríguez-Martín, A. Martínez-Feito, C. Plasencia-Rodríguez, A. Balsa, M L. Alonso-Pacheco, LM. Villar, P. Herranz-Pinto, D. Pascual-Salcedo
Wiley-Blackwell
0007-0963
00070963
1365-2133
13652133
shingle_title_1 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
shingle_title_2 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
shingle_title_3 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
shingle_title_4 Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
timestamp 2025-06-30T23:33:27.383Z
titel Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
titel_suche Differential blood cellular profile in patients with moderate to severe psoriasis treated with classical systemic therapies: A step forward in personalised medicine
topic WW-YZ
uid ipn_articles_6201722